-
Xu Jinghe meets with French ambassador to China
Xu Jinghe, Deputy Commissioner of China's National Medical Products Administration (NMPA), met with a delegation led by French Ambassador to China Bertrand Lortholary on March 18, to discuss enhancing cooperation in the cosmetics regulation.
-
Opinions of the General Office of the State Council on Comprehensively Deepening the Reform of Regulation of Drugs and Medical Devices to Promote the High-Quality Development of the Pharmaceutical Industry
In order to thoroughly implement the important instructions and directives of General Secretary Xi Jinping on the regulation of drugs and medical devices and the development of the pharmaceutical industry, and to comprehensively deepen reforms in drug and medical device regulation to promote the high-quality development of the pharmaceutical industry, the following opinions are proposed with the approval of the State Council.
-
Measures facilitate approval of 48 first-in-class innovative drugs
China approved 48 first-in-class innovative drugs, as well as a significant number of medications for pediatric and rare diseases, thanks to measures aimed at enhancing review efficiency and accelerating patient access to novel therapies, according to a report released on Tuesday by the National Medical Products Administration.
- NMPA Announcement on the Applicability of ICH Guideline E11A: Pediatric Extrapolation (No. 139, 2024)
- NMPA Announcement on the Applicability of ICH Guideline M12: Drug Interaction Studies and Its Q&A Document (No. 130, 2024)
- NMPA Announcement on Issuing the Interim Provisions on the Management of Designated Domestic Responsible Persons by Overseas Marketing Authorization Holders
